|
Michael M. Wick, M.D., Ph.D. is Chairman and Chief Executive Officer of Telik, Inc. (Nasdaq: TELK). He joined Telik in 1997 from CV Therapeutics, Inc. where he was Senior Vice President of Research and Development. Prior to joining CV Therapeutics, Dr. Wick was Executive Director of Oncology/Immunology and Clinical Research at Lederle Laboratories, a division of American Cyanamid, where he also directed the Cyanamid/Immunex joint oncology research program. Dr. Wick began his career at Harvard Medical School, where he was an Associate Professor. He also was Chief of the Melanoma Clinic and Laboratory of Molecular Dermatological Oncology at the Dana Farber Cancer Institute. Dr. Wick holds a Ph.D. in chemistry from Harvard University and an M.D. from Harvard Medical School. | 